# US 6,730,485 B2 · Methods for identifying ligand binding sites in a biomolecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,485 B2
- Document ID: US6730485B2
- Status: Granted
- Kind: B2
- Application number: 10/210,684
- Filed: 2002-07-31
- Published: 2003-01-16
- Granted: 2004-05-04
- Earliest claimed: 2001-02-22
- Assignees: Isis Pharmaceuticals, Inc.
- Inventors: Richard H. Griffey; Steven A. Hofstadler; Eric E. Swayze
- Web page: https://patentgrep.com/patent/US6730485B2

## CPC

- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Q 1/6811: Selection methods for production or design of target specific oligonucleotides or binding molecules
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of identifying ligand binding sites in a target molecule such as a polynucleotide or polypeptide, as well as methods for determining whether a particular site in a target molecule is at or near the ligand binding site, are provided. Ligand binding affinities corresponding to both the target molecule and a modified version thereof are compared, preferably using mass spectral analysis. The modified molecules, or test molecules, incorporate a modification capable of modulating ligand binding affinity when located at or near the ligand binding sites. Binding site information is derived from the known position of the modification.

## Claims

### Claim 1

A method for testing whether a predetermined position in a target molecule is at or proximate to a ligand binding site in said target molecule comprising:
(a) contacting a ligand with said target molecule under conditions that allow formation of a complex between said target molecule and said ligand;
(b) contacting said ligand with a test molecule under conditions that allow formation of a complex between said test molecule and said ligand, wherein said test molecule is said target molecule comprising a modification at a predetermined position, wherein said modification is capable of modulating ligand binding affinity when said modification is located at or proximate to said ligand binding site in said target molecule;
(c) comparing the relative amount of target molecule-ligand complex to the relative amount of test molecule-ligand complex using a mass spectrometer; and
(d) determining whether said predetermined position in said target molecule is at or proximate to said ligand binding site, wherein a difference in the relative amounts of target molecule-ligand complex and test molecule-ligand complex indicates that said ligand binds at or proximate to said predetermined position in said target molecule.

### Claim 2 (depends on 1)

The method of claim 1 wherein said target molecule comprises a polynucleotide, oligonucleotide, nucleic acid, peptide nucleic acid, RNA, DNA, or RNA/DNA hybrid.

### Claim 3 (depends on 1)

The method of claim 1 wherein said target molecule comprises a peptide, polypeptide, protein, receptor, or antibody.

### Claim 4 (depends on 1)

The method of claim 1 wherein said target molecule comprises an oligosaccharide, carbohydrate, or glycoprotein.

### Claim 5 (depends on 1)

The method of claim 1 wherein said test molecule comprises a modified nucleotide.

### Claim 6 (depends on 5)

The method of claim 5 wherein said modified nucleotide comprises a modified nucleobase.

### Claim 7 (depends on 6)

The method of claim 6 wherein said modified nucleobase comprises 5-substituted pyrimidines, 5-iodouracil, 5-iodocytosine, C5-propynyl pyrimidines, C5-propynylcytosine, C5-propynyluracil, N4—(C1-C12)alkylaminocytosines, N4,N4—(C1-C12) dialkylaminocytosines, 7-substituted-8-aza-7-deazapurines, 7-substituted-7-deazapurines, 7-iodo-7-deazapurines, 7-cyano-7-deazapurines, 7-aminocarbonyl-7-deazapurines, 6-amino-7-iodo-7-deazapurines, 6-amino-7-cyano-7-deazapurines, 6-amino-7-aminocarbonyl-7-deazapurines, 2-amino-6-hydroxy-7-iodo-7-deazapurines, 2-amino-6-hydroxy-7-cyano-7-deazapurines, 2-amino-6-hydroxy-7-aminocarbonyl-7-deazapurines, N6—(C1-C12)alkylaminopurines, N6, N6—(C1-C12)dialkylaminopurines, N6-methylaminoadenine, N6,N6-dimethylaminoadenine, 6-substituted purines, 6-thioguanine, 2-thiouracil, 8-bromoadenine, 8-bromoguanine, 2-fluoroadenine, or 2-fluoroguanine.

### Claim 8 (depends on 5)

The method of claim 5 wherein said modified nucleotide comprises a modified nucleosidic linking moiety.

### Claim 9 (depends on 8)

The method of claim 8 wherein said modified nucleosidic linking moiety comprises phosphorothioate, diphosphorothioate, alkylphosphonate, or amidate.

### Claim 10 (depends on 5)

The method of claim 5 wherein said modified nucleotide comprises a modified ribose moiety.

### Claim 11 (depends on 10)

The method of claim 10 wherein said modified ribose moiety comprises 2′ modifications selected from the group consisting of 2′-deoxy, 2′-O—(C1-C40)alkyl, 2′-O-methyl, 2′-O-allyl, 2′-O-dimethylaminoethyl, 2′-O-methoxyethoxy, 2′-fluoro, 2′-amino, 2′-thio, and 2′-thiomethyl.

### Claim 12 (depends on 1)

The method of claim 1 wherein said test molecule comprises a modified amine acid.

### Claim 13 (depends on 12)

The method of claim 12 wherein said modified amino acid is alanine.

### Claim 14 (depends on 1)

The method of claim 1 wherein either or both of said target molecule and said test molecule comprise at least one mass tag.

### Claim 15 (depends on 14)

The method of claim 14 wherein said mass tag comprises polymer.

### Claim 16 (depends on 15)

The method of claim 15 wherein said polymer comprises polyethylene glycol, polypropylene, polystyrene, cellulose, sephadex, dextran, peptide, or polyacrylamide.

### Claim 17 (depends on 1)

The method of claim 1 wherein said mass spectrometer is capable of producing detectable ions by electrospray ionization, atomospheric pressure ionization, or matrix-assisted laser desorption ionization.

### Claim 18 (depends on 1)

The method of claim 1 wherein said mass spectrometer includes mass analysis by quadrupole, quadrupole ion trap, time-of-flight, FT-ICR, or hybrid mass detectors.

### Claim 19

A method for testing whether a predetermined position in a polynucleotide target molecule is at or proximate to a ligand binding site comprising:
(a) contacting a ligand with said polynucleotide target molecule under conditions that allow formation of a complex between said target molecule and said ligand;
(b) contacting said ligand with a test molecule under conditions that allow formation of a complex between said test molecule and said ligand, wherein said test molecule is said target molecule comprising a modification at a predetermined position wherein said modification is capable of modulating ligand binding affinity when said modification is located at or proximate to said ligand binding site in said target molecule;
(c) comparing the ligand binding affinity of said polynucleotide target molecule-ligand complex with the ligand binding affinity of test molecule-ligand complex; and
(d) determining whether said predetermined position in said polynucleotide target molecule is at or proximate to said ligand binding site, wherein a difference in the ligand binding affinities of said polynucleotide target molecule-ligand complex and said test molecule-ligand complex indicates that said ligand binds at or proximate to said predetermined position in said polynucleotide target molecule.
